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evidence­based standard for invasive evaluation 
of such lesions, but it now appears that iFR may 
be the new standard.
A statistical consultant for the Journal performed the meta­
analysis of the two trials discussed in the editorial.
Disclosure forms provided by the author are available with the 
full text of this editorial at NEJM.org.
From Brigham and Women’s Hospital Heart and Vascular Cen-
ter and Harvard Medical School — both in Boston. 
This editorial was published on March 18, 2017, at NEJM.org.
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New Lessons about Endometriosis — Somatic Mutations  
and Disease Heterogeneity
Grant W. Montgomery, Ph.D., and Linda C. Giudice, M.D., Ph.D.
Endometriosis is a common estrogen­dependent 
inflammatory disorder that affects 6 to 10% of 
women of reproductive age and up to 50% 
of women with infertility and pelvic pain.1 Endo­
metriosis is a complex disease with risk influ­
enced by many factors; its pathogenesis is poorly 
understood, and current treatments have limita­
tions.2 A role for genetics is well established, 
with approximately 50% of risk due to genetic 
factors and 50% due to environmental or other 
causes.3 The disease is heterogeneous, with mul­
tiple ectopic lesions containing endometrial­like 
tissue outside the uterus, primarily in the pelvic 
cavity.1 The lesions may be one of three types: 
superficial peritoneal lesions, ovarian endometri­
omas, or deep infiltrating endometriosis. Histo­
logic analysis of the lesions suggests that endo­
metriosis is benign, but it shares features of 
cancer because lesions attach and invade other 
tissues. Symptoms of pain and infertility do not 
correlate well with the appearance of lesions, 
although pain correlates well with deep infiltrat­
ing disease. Histologic appearance and response 
to treatment vary according to lesion site, with 
more undifferentiated endometriosis in areas of 
deep infiltrating endometriosis.4 The heterogene­
ity of lesions, disease course, and symptoms 
raises important questions about whether endo­
metriosis is one disease or whether different 
subtypes with different underlying causes exist.
The exome­sequencing study on samples from 
deep infiltrating endometriosis lesions reported 
by Anglesio and colleagues in this issue of the 
Journal 5 provides interesting results and shows 
further complexity of the disorder. They identi­
fied somatic mutations in lesions from 19 of 24 
patients (79%). The number of mutations in each 
lesion was variable. Lesions from 5 patients (21%) 
harbored known somatic cancer driver muta­
tions in ARID1A, PIK3CA, KRAS, and PPP2R1A. 
More detailed experiments on samples from 
3 other patients revealed KRAS mutations in 2 of 
them. One patient had two different activating 
KRAS mutations, and the other patient had the 
same somatic KRAS mutation in three separate 
lesions. Lesions contain multiple cell types, and 
KRAS mutations were detected only in the epi­
thelium and not in the stroma.
Cancer­associated somatic mutations in deep 
infiltrating endometriosis suggest that they may 
contribute to the development of some deep in­
filtrating lesions. The observation of the same 
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KRAS mutation in three different lesions in one 
patient supports the view that the mutation prob­
ably occurred at an early stage. As the authors 
noted, some cases of endometriosis do undergo 
malignant transformation.5 There is genetic over­
lap in risk of endometriosis and ovarian cancer, 
with the strongest genetic correlation between 
endometriosis and ovarian clear­cell carcinoma.6 
Somatic mutations in ARID1A or PIK3CA have 
been reported in ovarian clear­cell carcinomas 
and associated endometriotic lesions from the 
same patients.7 Transformation of cells may 
have occurred in these lesions, with subsequent 
progression to ovarian cancer. However, malig­
nant transformation of deep infiltrating endo­
metriosis rarely occurs. This suggests that one 
copy of the mutation is not sufficient for malig­
nant transformation of these cells, and additional 
DNA replication errors seldom occur in deep 
infiltrating endometriosis.
The variable patterns of somatic mutation in 
deep infiltrating endometriosis lesions are in­
triguing. Do specific mutations in these lesions 
contribute to severity and progression? Are so­
matic mutations observed in the other types of 
lesions or in endometrial precursor cells? If so, 
is the spectrum of mutations similar in different 
types of lesions or are the patterns distinct, pro­
viding a partial explanation for different disease 
presentations in different patients? The studies 
will not be straightforward because of difficul­
ties in obtaining sufficient tissue suitable for the 
genetic studies (especially from peritoneal lesions). 
The mutations appear to occur in only one cell 
type (epithelium), resulting in low allele frequen­
cies in mixed tissue samples that could be dif­
ficult to detect.
Common germline variants account for ap­
proximately one quarter of the total risk of en­
dometriosis.8 Genomic regions that are associ­
ated with disease risk have been mapped,8,9 and 
the likely target genes within these regions are 
beginning to be identified.10 The results show 
that genetic risk factors are likely to influence 
lesion formation leading to clinical disease 
through changes in gene expression in the endo­
metrium from which most pelvic disease derives 
by monthly retrograde menstruation through the 
oviducts. Comparison of gene lists from genetic 
studies and the spectrum of somatic mutations 
in lesions should potentially provide clues about 
whether the mechanisms are related or act inde­
pendently. The current study detected an in­frame 
deletion mutation in ID4 in one patient; this 
gene has been strongly implicated in genetic as­
sociation studies.9
The application of these methods for sequenc­
ing lesions (now widely used in cancer research) 
and progress in genetics are improving knowl­
edge of genomic changes in all forms of endo­
metriosis. Answers to long­standing questions 
about variability in disease presentation and 
greater understanding of genes altered by so­
matic changes may also provide new insights 
into disease pathogenesis and heterogeneity to 
better inform diagnosis, clinical practice, and 
treatment options in ways similar to improved 
treatments for specific cancer subtypes.
Disclosure forms provided by the authors are available with 
the full text of this editorial at NEJM.org.
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